Effects of Exercise in Patients With Ulcerative Colitis

January 4, 2023 updated by: Adora Yau, Manchester Metropolitan University

The Effects of Exercise Intensity on Gastrointestinal Function and Inflammatory Markers in Patients With Ulcerative Colitis

The aim of this study is to investigate the effects of moderate to high intensity exercise on gut function and inflammatory markers in patients with Ulcerative Colitis (UC), and to compare them with individuals of matched age who do not suffer from Inflammatory Bowel Disease. Participants will be asked to complete 60 minutes of continuous cycling at a moderate to high intensity followed by a three hour recovery period. Gastrointestinal function will be measured using a non-invasive breath test. Blood samples will be collected at multiple time-points during the visit and these samples will be measured for markers of immune function and intestinal integrity.

Study Overview

Status

Suspended

Intervention / Treatment

Detailed Description

There is limited research on the effect of exercise on patients with Ulcerative Colitis. The aim of this investigation is to study the acute effects of moderate to high intensity exercise on gut function in patients with Ulcerative Colitis and to compare them with individuals of matched age who do not suffer from Inflammatory Bowel Disease.

Patients in remission from disease activity and age and gender matched healthy control participants will be recruited from the general population. Participants will attend the laboratory on two occasions. The first visit will last approximately one hour and will include an exercise test to determine peak oxygen uptake capacity (VO2peak) which is an indicator of cardiorespiratory fitness. The second visit will last for approximately four and a half hours and will consist of a 60 minute continuous cycle on a stationary cycle ergometer at an intensity of 65% VO2peak followed by a recovery period. Gastric emptying rate of a commercially available sports drink will be measured and blood samples will be collected at regular time-points throughout the visit and analysed for concentrations of inflammatory markers and intestinal integrity/function.

Study Type

Interventional

Enrollment (Anticipated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Greater Manchester
      • Manchester, Greater Manchester, United Kingdom, M1 5GD
        • Manchester Metropolitan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

For ulcerative colitis patients;

  • Currently in remission of disease (asymptomatic at time of experiment)
  • Less than 3 periods of disease activity (periods of symptomatic activity) in the last 12 months
  • No history of surgery to alleviate condition severity
  • Taking regular standard medication for control of condition
  • Adult less than 50 years due to effects of exercise in older age
  • Non-smokers
  • Regular exercisers (determined via verbal discussion)

For healthy controls;

  • No history of disease (as assessed by standard medical screening questionnaire)
  • Adult less than 50 years due to effects of exercise in older age
  • Non-smokers
  • Regular exercisers (determined via verbal discussion)

Exclusion Criteria:

For ulcerative colitis patients;

  • Currently in active period of disease (symptomatic at time of experiment)
  • More than 3 periods of disease activity (periods of symptomatic activity) in the last 12 months
  • History of surgery to alleviate condition severity
  • Taking non-standard medication for control of condition
  • Adult more than 50 years of age
  • Under 18 years of age
  • Smokers
  • Sedentary or not regularly physically active (determined via verbal discussion)

For healthy controls;

  • History of disease (as assessed by standard medical screening questionnaire)
  • Adult more than 50 years of age
  • Under 18 years of age
  • Smokers
  • Sedentary or not regularly physically active (determined via verbal discussion)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: UC Patients
Patient group
60 minutes of continuous exercise at 65% VO2peak and drink ingestion
Active Comparator: Healthy controls
Control group
60 minutes of continuous exercise at 65% VO2peak and drink ingestion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in inflammatory markers or hormones
Time Frame: 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Circulating concentrations of Interleukin-6, Tumor Necrosis Factor-alpha, C-reactive protein, glucagon like peptide 2
6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Area under the circulating concentration versus time curve (AUC) of inflammatory markers or hormones
Time Frame: 4.5 hours
Responses of Interleukin-6, Tumor Necrosis Factor-alpha, C-reactive protein, glucagon like peptide 2
4.5 hours
Change in intestinal epithelial damage and permeability markers
Time Frame: 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Circulating concentrations of intestinal fatty acid binding protein and claudin-3
6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Area under the circulating concentration versus time curve (AUC) of intestinal epithelial damage and permeability markers
Time Frame: 4.5 hours
Responses of intestinal fatty acid binding protein and claudin-3
4.5 hours
Change in exercise induced endotoxaemia markers
Time Frame: 6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Circulating concentrations of plasma lipopolysaccharide
6 blood samples collected at baseline, 30 minutes of exercise (mid exercise), immediately post exercise bout, then every 60 minutes post exercise for 3 hours
Area under the circulating concentration versus time curve (AUC) of exercise induced endotoxaemia markers
Time Frame: 4.5 hours
Response of plasma lipopolysaccharide
4.5 hours
Gastric emptying rate half time and time of maximal emptying rate
Time Frame: 2 hours after ingestion of drink
Emptying rate of a commercially available sports drink from the stomach using the 13C breath test method
2 hours after ingestion of drink
Change in ratio of 13C/12C in breath samples
Time Frame: 9 breath samples collected at baseline, then every 15 minutes after ingestion for 2 hours
Gastric emptying profile of a commercially available sports drink from the stomach using the 13C breath test method
9 breath samples collected at baseline, then every 15 minutes after ingestion for 2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence and severity of gastrointestinal symptoms
Time Frame: Immediately post-exercise bout and 3 hours post exercise.
10-point rating scale for gastrointestinal symptoms (Visual Analogue Scale modified). 19 item questionnaire with 5 subcategories (Overall gut discomfort, total gastrointestinal symptoms, upper gastrointestinal symptoms, lower gastrointestinal symptoms and other gastrointestinal symptoms). Scores for each item ranging from 0 (no symptom) to 10 (extremely severe symptoms causing exercise reduction, stopping, or complete withdrawal). Higher scores represent higher severity of symptoms.
Immediately post-exercise bout and 3 hours post exercise.
Heart rate response
Time Frame: Every 5 minutes during 60 minute cycle
Heart rate telemetry
Every 5 minutes during 60 minute cycle
Disparity of subjective exertion and objective cardiorespiratory parameters
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and cardiopulmonary exercise testing variables of oxygen uptake, carbon dioxide expiration, ventilatory threshold, volume of air expired, and tidal volume (all parameters measured in L/min).
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Disparity of subjective exertion and objective heart rate
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and heart rate measured by telemetry
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Disparity of subjective exertion and breathing frequency
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and number of breaths per minute
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Disparity of subjective exertion and oxygen pulse
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and oxygen pulse calculated by dividing oxygen uptake by heart rate.
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Disparity of subjective exertion and respiratory exchange ratio
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and respiratory exchange ratio calculated by dividing carbon dioxide production by oxygen uptake.
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Disparity of subjective exertion and ventilatory efficiency
Time Frame: Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Regression of ratings of perceived exertion (RPE; Borg scale, minimum value 6 representing no exertion, maximum value 20 representing maximal exertion. Higher scores represent higher perceived exertion) and minute ventilation/carbon dioxide slope (VE/VCO2 slope).
Every minute during the peak oxygen uptake test that typically lasts between 8-12 minutes
Subjective physical activity levels
Time Frame: Prior to experimental trial
International Physical Activity Questionnaire (IPAQ). Answers to questions (time spent completing different physical activities) converted to Metabolic Equivalent (METs) hours per week. Minimum value of zero, no limit to maximum. Higher MET values indicate higher physical activity levels.
Prior to experimental trial
Attitudes and beliefs towards physical activity
Time Frame: Prior to experimental trial
Barriers to Physical Activity Questionnaire. 21 item questionnaire, each question rated from 0 (very unlikely) to 3 (very likely). Each item belongs to one of 7 categories relating to barriers to physical activity. Score totals greater than 5 indicate the category as being a significant barrier.
Prior to experimental trial
Subjective health related quality of life: RAND 36-Item Short Form Health Survey (SF-36)
Time Frame: Prior to experimental trial
RAND 36-Item Short Form Health Survey (SF-36). 36-item questionnaire covering 8 concepts; physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions, plus single item providing an indication of perceived change in health. Scores ranging from 0 to 100 for each concept with 100 indicating good health and 0 being poor health.
Prior to experimental trial

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Gethin H Evans, PhD, Manchester Metropolitan University
  • Principal Investigator: Adora MW Yau, PhD, Manchester Metropolitan University
  • Principal Investigator: John McLaughlin, Prof., University of Manchester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2019

Primary Completion (Anticipated)

September 1, 2024

Study Completion (Anticipated)

December 1, 2025

Study Registration Dates

First Submitted

October 15, 2019

First Submitted That Met QC Criteria

October 28, 2019

First Posted (Actual)

October 29, 2019

Study Record Updates

Last Update Posted (Actual)

January 5, 2023

Last Update Submitted That Met QC Criteria

January 4, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Planned communication of group results at a scientific conference. Planned publication in a scientific peer reviewed journal. Participant level data is not expected to be available as this complies with the conditions of the ethical approval granted for this study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Bowel Diseases

Clinical Trials on Exercise

Subscribe